ICCC
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B of 2.37 is moderate, but lack of earnings makes traditional valuation impossible.
- Reasonable Price/Sales ratio (2.32)
- No Graham Number available
- Negative earnings preclude P/E valuation
Revenue contraction is a major red flag for a biotechnology firm.
- Recent EPS surprise beats
- Negative YoY and Q/Q revenue growth
- Forward P/E is deeply negative (-64.32)
Short-term recovery is not yet supported by long-term historical performance.
- Strong 1-year price return (+39.6%)
- Negative 5-year price change (-21.2%)
High liquidity is the only factor preventing a total health collapse.
- High Current Ratio (4.26)
- Low Debt/Equity (0.49)
- Piotroski F-Score of 2/9 indicates severe fundamental weakness
Typical for biotech, but provides no yield support.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ICCC and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ICCC
ImmuCell Corporation
Primary
|
-21.2% | +44.8% | +39.6% | +4.1% | +6.5% | +9.9% |
|
ATHE
Alterity Therapeutics Limited
Peer
|
-80.8% | -8.5% | +6.3% | -45.8% | +14.5% | +2.9% |
|
FORA
Forian Inc.
Peer
|
-82.8% | -35.5% | +13.5% | -7.0% | +2.9% | +1.9% |
|
DCGO
DocGo Inc.
Peer
|
-94.3% | -93.1% | -77.6% | -55.1% | -15.2% | -9.4% |
|
BTMD
biote Corp.
Peer
|
-85.2% | -74.7% | -54.1% | -47.5% | -16.8% | +10.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ICCC
ImmuCell Corporation
|
BEARISH | $64.01M | - | -3.8% | -3.8% | $7.08 | |
|
ATHE
Alterity Therapeutics Limited
|
BEARISH | $64.35M | - | -43.2% | -223.3% | $3.55 | Compare |
|
FORA
Forian Inc.
|
BEARISH | $66.86M | - | -9.6% | -9.5% | $2.14 | Compare |
|
DCGO
DocGo Inc.
|
BEARISH | $56.28M | - | -89.0% | -56.6% | $0.57 | Compare |
|
BTMD
biote Corp.
|
NEUTRAL | $55.53M | 2.01 | -% | 14.1% | $1.49 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | BRIGHAM MICHAEL F | Director | Option Exercise | 25,000 | $146,000 |
| 2025-12-04 | TE BOEKHORST PAUL FRANCIS OLIVIER | Chief Executive Officer | Purchase | 9,738 | $49,581 |
| 2025-12-03 | TE BOEKHORST PAUL FRANCIS OLIVIER | Chief Executive Officer | Purchase | 9,785 | $48,588 |
| 2025-11-25 | TOMSCHE DAVID SCOTT | Director | Purchase | 3,266 | $15,554 |
Past News Coverage
Recent headlines mentioning ICCC from our newsroom.